University of Hertfordshire

The increasing indications of FDG-PET/CT in Bladder Cancer

Research output: Contribution to journalArticlepeer-review

Standard

The increasing indications of FDG-PET/CT in Bladder Cancer. / Omorphos, Nicolas; Ghose, Aruni; Hayes, John; Kandala, Abhinav; Dasgupta, Prokar; Sharma, Anand; Vasdev, Nikhil.

In: European Urology, 04.10.2021.

Research output: Contribution to journalArticlepeer-review

Harvard

Omorphos, N, Ghose, A, Hayes, J, Kandala, A, Dasgupta, P, Sharma, A & Vasdev, N 2021, 'The increasing indications of FDG-PET/CT in Bladder Cancer', European Urology.

APA

Omorphos, N., Ghose, A., Hayes, J., Kandala, A., Dasgupta, P., Sharma, A., & Vasdev, N. (2021). The increasing indications of FDG-PET/CT in Bladder Cancer. Manuscript submitted for publication.

Vancouver

Omorphos N, Ghose A, Hayes J, Kandala A, Dasgupta P, Sharma A et al. The increasing indications of FDG-PET/CT in Bladder Cancer. European Urology. 2021 Oct 4.

Author

Omorphos, Nicolas ; Ghose, Aruni ; Hayes, John ; Kandala, Abhinav ; Dasgupta, Prokar ; Sharma, Anand ; Vasdev, Nikhil. / The increasing indications of FDG-PET/CT in Bladder Cancer. In: European Urology. 2021.

Bibtex

@article{184cae62673a46c29806a7839dfcef1f,
title = "The increasing indications of FDG-PET/CT in Bladder Cancer",
abstract = "ContextThe management of locally advanced Muscle Invasive Bladder Cancer (MIBC) often necessitates neo-adjuvant chemotherapy (NAC) to downstage the disease prior to definitive radical cystectomy (RC) and pelvic lymph node dissection (PLND). Assessing tumour response to NAC is crucial prior to planning definitive surgical treatment.ObjectiveReview the evolving indications of functional F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (FDG-PET/CT) imaging in MIBC.ConclusionFDG-PET/CT is being increasingly utilised in local nodal staging and detection of metastatic disease in MIBC. Furthermore, it appears more accurate than conventional imaging modalities (CT/MRI) in assessing tumour response to NAC. This enables the earlier detection of tumour response and/or residual disease, impacting factors such as the duration of chemotherapy, with its associated adverse effects, and the timing of surgical intervention.Patient SummaryAdvanced bladder cancer that has invaded the muscle requires a combination treatment that may include chemotherapy prior to surgical removal of the bladder. The use of new imaging techniques, such as FDG-PET/CT, enables more accurate initial staging of bladder cancer (involvement of local lymph nodes or distant organs). In addition, it appears to be better at assessing cancer response to chemotherapy,compared to the more traditional CT and MRI imaging.",
author = "Nicolas Omorphos and Aruni Ghose and John Hayes and Abhinav Kandala and Prokar Dasgupta and Anand Sharma and Nikhil Vasdev",
year = "2021",
month = oct,
day = "4",
language = "English",
journal = "European Urology",
issn = "0302-2838",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - The increasing indications of FDG-PET/CT in Bladder Cancer

AU - Omorphos, Nicolas

AU - Ghose, Aruni

AU - Hayes, John

AU - Kandala, Abhinav

AU - Dasgupta, Prokar

AU - Sharma, Anand

AU - Vasdev, Nikhil

PY - 2021/10/4

Y1 - 2021/10/4

N2 - ContextThe management of locally advanced Muscle Invasive Bladder Cancer (MIBC) often necessitates neo-adjuvant chemotherapy (NAC) to downstage the disease prior to definitive radical cystectomy (RC) and pelvic lymph node dissection (PLND). Assessing tumour response to NAC is crucial prior to planning definitive surgical treatment.ObjectiveReview the evolving indications of functional F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (FDG-PET/CT) imaging in MIBC.ConclusionFDG-PET/CT is being increasingly utilised in local nodal staging and detection of metastatic disease in MIBC. Furthermore, it appears more accurate than conventional imaging modalities (CT/MRI) in assessing tumour response to NAC. This enables the earlier detection of tumour response and/or residual disease, impacting factors such as the duration of chemotherapy, with its associated adverse effects, and the timing of surgical intervention.Patient SummaryAdvanced bladder cancer that has invaded the muscle requires a combination treatment that may include chemotherapy prior to surgical removal of the bladder. The use of new imaging techniques, such as FDG-PET/CT, enables more accurate initial staging of bladder cancer (involvement of local lymph nodes or distant organs). In addition, it appears to be better at assessing cancer response to chemotherapy,compared to the more traditional CT and MRI imaging.

AB - ContextThe management of locally advanced Muscle Invasive Bladder Cancer (MIBC) often necessitates neo-adjuvant chemotherapy (NAC) to downstage the disease prior to definitive radical cystectomy (RC) and pelvic lymph node dissection (PLND). Assessing tumour response to NAC is crucial prior to planning definitive surgical treatment.ObjectiveReview the evolving indications of functional F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (FDG-PET/CT) imaging in MIBC.ConclusionFDG-PET/CT is being increasingly utilised in local nodal staging and detection of metastatic disease in MIBC. Furthermore, it appears more accurate than conventional imaging modalities (CT/MRI) in assessing tumour response to NAC. This enables the earlier detection of tumour response and/or residual disease, impacting factors such as the duration of chemotherapy, with its associated adverse effects, and the timing of surgical intervention.Patient SummaryAdvanced bladder cancer that has invaded the muscle requires a combination treatment that may include chemotherapy prior to surgical removal of the bladder. The use of new imaging techniques, such as FDG-PET/CT, enables more accurate initial staging of bladder cancer (involvement of local lymph nodes or distant organs). In addition, it appears to be better at assessing cancer response to chemotherapy,compared to the more traditional CT and MRI imaging.

M3 - Article

JO - European Urology

JF - European Urology

SN - 0302-2838

ER -